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Editorial 
While the majority of breast cancer cases are 
sporadic, up to 30% have been described as familial. 
Hereditary breast cancer, accounting for approximately 
10% of breast cancer cases, has classically been 
associated with highly penetrant gene mutations that are 
highly likely to cause cancer, vertical transmission, 
autosomal dominant inheritance pattern, association 
with other cancers, and early age of onset.
1-5
 In contrast, 
these characteristics are often not exhibited in familial 
breast cancers. Therefore, although familial breast 
cancers occur more in an individual family than in the 
general population, they are thought to be due to a 
complex interaction between lower penetrance genes 
and environmental factors and/or random intra-familial 
sporadic cancer cases.
3-5
 
In 1994, inherited mutations in BRCA1 and 
BRCA2 genes that encode for tumor suppressor proteins 
were linked to hereditary breast and ovarian cancer.
6,7
 
Since this groundbreaking scientific discovery, much 
has been learned about genetic risk of breast cancer 
(such as newer detection techniques with improved 
sensitivity to detect BRCA1 and BRCA2 large genomic 
rearrangements);
8
 however, many BRCA-related 
questions remain unanswered. The prevalence of known 
deleterious BRCA1 and BRCA2 gene mutations is 
approximately 1 in 400 individuals.
9
 Due to variable 
penetrance, the probability of cancer development 
varies amongst BRCA mutation carriers, (even amongst 
carriers in families with the same mutation),
10
 but in 
general, BRCA deleterious mutations confer a 45-84% 
lifetime risk for breast cancer.
11
 It is, therefore, not 
surprising that known deleterious BRCA mutations are 
variable across different ethnic and geographic 
populations. Moreover, founder mutations have been 
identified within Ashkenzi Jewish, Icelandic, and other 
populations.  
When discussing BRCA1 and BRCA2 
sequence variants, the terminology can be difficult to 
discern. Variations that confer increased cancer risk are 
termed “deleterious mutations,” but a number of other 
changes in BRCA1 and BRCA2 are rapidly emerging, 
the significance of which are less clear. It is important, 
therefore, to use consistent language when discussing 
such findings. Mutations and polymorphisms are both 
sequence variants. The term “mutation” signifies any 
rare deviation in the DNA sequence of a gene from the 
normal wild type. Polymorphisms, on the other hand, 
are common variations in DNA that are generally 
considered to occur with a frequency greater than 1%.
12
 
If a polymorphism is known to be disease-causing, then 
it will typically be referred to as a deleterious mutation, 
although most, but not all, deleterious mutations are 
seen at a lower frequency in the population.  
Polymorphisms include, but are not limited to: single 
nucleotide polymorphisms (SNPs), insertions, deletions, 
or repeated sequences.  SNPs are the most common type 
of polymorphism accounting for approximately 90% of 
all human genetic variation.
13
 Most SNPs are benign or 
neutral polymorphisms with no known clinical impact; 
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however, it is thought that some may provide useful 
clinical information, such as likelihood of developing 
disease, response to disease, and perhaps implications 
for treatment.
14
 
Polymorphisms and mutations can be further 
classified as synonymous or non-synonymous based on 
their impact on the resulting amino acid. A synonymous 
substitution results in a codon that does not lead to a 
change in the coded amino acid, whereas non-
synonymous substitutions, such as missense mutations, 
do result in an amino acid change. Lastly, variants of 
uncertain significance (VUS) are novel DNA changes 
with unknown effects on protein function and disease 
risk. Pending further investigation, an identified VUS 
could be reclassified as a deleterious mutation or a 
polymorphism of no clinical significance in the future.
15
 
In the current publication, Akilzhanova and 
colleagues examine the role of BRCA1 and 2 mutations 
in Kazakhstan women with sporadic breast cancer. They 
studied genomic DNA from 156 sporadic breast cancer 
cases (defined as women without family history of 
affected first- or second- degree relatives with breast 
and/or ovarian cancer) and 112 controls (matched on 
age and ethnicity) from two different areas in 
Kazakhstan. Ultimately, mutational screening of 
BRCA1 and BRCA2 coding regions for these patients 
and controls identified 22 distinct variants (16 missense 
mutations of unknown clinical significance and 6 
polymorphisms). No deleterious BRCA1 or 2 mutations 
were identified. There were significantly more variants 
in the Caucasians versus the Asian breast cancer cases 
and more variants in the Asian versus the Caucasian 
controls. They also found a number of women (79 of 
156, 71%) who carried 4-6 alterations. This makes these 
alterations in the BRCA sequence much less likely to be 
deleterious, particularly if they were the same sequence 
variants that they termed “likely neutral 
polymorphisms,” (those that were expressed at a high 
frequency in both cases and controls).  
Models incorporating variables from cancer 
history of patients as well as multiple other factors into 
logistic regression analyses potentially have the ability 
to segregate uncertain BRCA1 and BRCA2 variants into 
deleterious and non-deleterious categories.
16-22
 These 
models work best when there are enough occurrences of 
a single variant amongst unrelated families to help aid 
in its classification. We are still limited in finding ways 
to classify variants that occur rarely in a specific 
region.
23
 
Several resources exist for obtaining 
information regarding previously identified VUS and 
SNPs including: the SNP Consortium,
24
 the dbSNP 
database from the National Center for Biotechnology 
Information (NCBI), the Breast Cancer Information 
Core (BIC) (http://research.nhgri.nih.gov/bic/), and 
HGVbase (Human Genome Variation Database), which 
is a human gene-based polymorphism database.  Due to 
the difficulty in screening the literature in order to 
determine whether a specific variant of uncertain 
significance has been classified, reporting variants to 
such large comprehensive databases of BRCA1 and 2 
genes is critically important. Additionally, there is an 
ENIGMA consortium that has been established to 
evaluate the significance of uncertain variants in high-
risk breast cancer genes. The success of this group can 
only be achieved by collecting genetic and clinical 
information, functional assays, and mRNA expression 
and splicing assays.
23
 
Via computational approaches, functional 
assay data has been shown to correlate well with 
pathogenicity of BRCA1 variants of uncertain 
significance.
25
 A guide for functional analysis of 
BRCA1 variants of uncertain significance has recently 
been published.
26
 Additionally, a five-tiered 
classification scheme for DNA sequence variants and 
correlation of clinical recommendation with probability 
that any given alteration is deleterious has been 
developed based on the posterior probability model, 
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with Class 1 and 2 being not likely pathogenic, class 3 
remaining a true VUS, and Class 4 and 5 considered 
pathogenic/deleterious for clinical purposes.
27,28
 As an 
example, the authors of the current publication found a 
BRCA1 amino acid variant of Pro871Leu, which is 
listed as Class 1, likely not pathogenic,
28
 which is 
consistent with the fact that it was found in about half of 
their total population, both in cases and controls.   
In conclusion, despite major advances in our 
BRCA testing, in many instances we are still in a very 
elementary stage in applying such information clinically 
toward the care of patients. It is only through 
collaboration that the rapidly developing field of 
molecular genetics will lead to advances in patient care.   
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